Compare Stocks: ALGS, OTLK, INDP, and CNTB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$6.22 +0.2%	$5.91	$3.98 ▼ $13.69	$38.78M	2.34	137,991 shs	42,055 shs
CNTB Connect Biopharma	$1.93 -30.1%	$2.29	$1.23 ▼ $3.82	$173.81M	-0.23	650,024 shs	3.73 million shs
INDP Indaptus Therapeutics	$1.16 -0.9%	$1.88	$0.92 ▼ $8.57	$155.89M	1.17	876,661 shs	249,915 shs
OTLK Oncobiologics	$0.65 +3.6%	$1.11	$0.16 ▼ $2.54	$152.47M	0.74	22.52 million shs	6.63 million shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	+0.16%	-12.02%	+30.95%	+26.68%	-42.41%
CNTB Connect Biopharma	-30.07%	-15.35%	-6.76%	-11.06%	-3.02%
INDP Indaptus Therapeutics	-0.85%	0.00%	-14.71%	-68.31%	-78.52%
OTLK Oncobiologics	+3.62%	+1.23%	-32.41%	-16.44%	-27.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$6.22 +0.2%	$5.91	$3.98 ▼ $13.69	$38.78M	2.34	137,991 shs	42,055 shs
CNTB Connect Biopharma	$1.93 -30.1%	$2.29	$1.23 ▼ $3.82	$173.81M	-0.23	650,024 shs	3.73 million shs
INDP Indaptus Therapeutics	$1.16 -0.9%	$1.88	$0.92 ▼ $8.57	$155.89M	1.17	876,661 shs	249,915 shs
OTLK Oncobiologics	$0.65 +3.6%	$1.11	$0.16 ▼ $2.54	$152.47M	0.74	22.52 million shs	6.63 million shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	+0.16%	-12.02%	+30.95%	+26.68%	-42.41%
CNTB Connect Biopharma	-30.07%	-15.35%	-6.76%	-11.06%	-3.02%
INDP Indaptus Therapeutics	-0.85%	0.00%	-14.71%	-68.31%	-78.52%
OTLK Oncobiologics	+3.62%	+1.23%	-32.41%	-16.44%	-27.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALGS Aligos Therapeutics	2.86	Moderate Buy	$38.50	518.97% Upside
CNTB Connect Biopharma	2.75	Moderate Buy	$7.43	284.90% Upside
INDP Indaptus Therapeutics	1.00	Sell	N/A	N/A
OTLK Oncobiologics	2.20	Hold	$5.20	701.23% Upside

Current Analyst Ratings Breakdown

Latest ALGS, OTLK, INDP, and CNTB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	CNTB Connect Biopharma	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.00
8/14/2026	OTLK Oncobiologics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$4.00
8/12/2026	OTLK Oncobiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/10/2026	ALGS Aligos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/28/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	OTLK Oncobiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/27/2026	OTLK Oncobiologics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$1.60
7/27/2026	OTLK Oncobiologics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00
7/17/2026	INDP Indaptus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/10/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALGS Aligos Therapeutics	$2.19M	17.72	N/A	N/A	$5.11 per share	1.22
CNTB Connect Biopharma	$60K	2,025.54	N/A	N/A	$0.43 per share	4.49
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	$0.09 per share	N/A
OTLK Oncobiologics	$1.35M	117.04	N/A	N/A	($0.04) per share	-16.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALGS Aligos Therapeutics	-$24.19M	-$7.30	N/A	N/A	N/A	-241.01%	-160.72%	-92.30%	11/5/2026 (Estimated)
CNTB Connect Biopharma	-$55.48M	-$1.19	N/A	N/A	N/A	N/A	-165.41%	-121.58%	11/11/2026 (Estimated)
INDP Indaptus Therapeutics	-$20.85M	-$6.33	N/A	N/A	N/A	N/A	-302.89%	-203.49%	11/17/2026 (Estimated)
OTLK Oncobiologics	-$62.42M	-$0.77	N/A	N/A	N/A	N/A	N/A	-254.82%	N/A

Latest ALGS, OTLK, INDP, and CNTB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q3 2026	OTLK Oncobiologics	-$0.08	-$0.09	-$0.01	-$0.15	$0.97 million	$0.01 million
8/13/2026	Q2 2026	INDP Indaptus Therapeutics	-$1.57	-$0.02	+$1.55	-$0.02	N/A	N/A
8/12/2026	Q2 2026	CNTB Connect Biopharma	-$0.3149	-$0.27	+$0.0449	-$0.27	$0.74 million	$2.75 million
8/6/2026	Q2 2026	ALGS Aligos Therapeutics	-$1.09	-$0.14	+$0.95	-$0.14	$24.68 million	$27.78 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	N/A
OTLK Oncobiologics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALGS Aligos Therapeutics	N/A	2.19	2.19
CNTB Connect Biopharma	0.01	2.37	2.37
INDP Indaptus Therapeutics	N/A	19.49	19.49
OTLK Oncobiologics	N/A	0.81	0.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALGS Aligos Therapeutics	60.43%
CNTB Connect Biopharma	58.72%
INDP Indaptus Therapeutics	7.06%
OTLK Oncobiologics	11.20%

Insider Ownership

Company	Insider Ownership
ALGS Aligos Therapeutics	7.80%
CNTB Connect Biopharma	22.60%
INDP Indaptus Therapeutics	9.94%
OTLK Oncobiologics	1.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALGS Aligos Therapeutics	90	6.24 million	5.76 million	No Data
CNTB Connect Biopharma	110	62.97 million	48.74 million	Optionable
INDP Indaptus Therapeutics	6	133.24 million	120.00 million	Not Optionable
OTLK Oncobiologics	20	243.45 million	239.07 million	Optionable

ALGS, OTLK, INDP, and CNTB Headlines

Recent News About These Companies

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

August 27, 2026 | globenewswire.com

Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

August 27, 2026 | globenewswire.com

Analysts Issue Forecasts for Oncobiologics FY2026 Earnings

August 21, 2026 | marketbeat.com

Brookline Capital Markets Comments on Oncobiologics Q1 Earnings

August 20, 2026 | marketbeat.com

OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp

August 17, 2026 | zacks.com

Short Interest in Oncobiologics, Inc. (NASDAQ:OTLK) Grows By 78.0%

August 17, 2026 | marketbeat.com

Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN)

August 15, 2026 | defenseworld.netD

Insider Buying: Oncobiologics (NASDAQ:OTLK) Director Acquires $2,499,999.48 in Stock

August 15, 2026 | insidertrades.com

Oncobiologics, Inc. (NASDAQ:OTLK) Given Average Rating of "Hold" by Brokerages

August 15, 2026 | marketbeat.com

Oncobiologics (NASDAQ:OTLK) Downgraded to "Sell" Rating by Wall Street Zen

August 15, 2026 | marketbeat.com

Oncobiologics (NASDAQ:OTLK) Director Ghiath Sukhtian Buys 2,525,252 Shares of Stock

August 14, 2026 | marketbeat.com

Oncobiologics (NASDAQ:OTLK) Releases Earnings Results

August 14, 2026 | marketbeat.com

Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript

August 14, 2026 | seekingalpha.com

Oncobiologics' (OTLK) Buy Rating Reaffirmed at BTIG Research

August 14, 2026 | marketbeat.com

Oncobiologics Q3 Earnings Call Highlights

August 14, 2026 | marketbeat.com

Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

August 14, 2026 | zacks.com

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

August 14, 2026 | globenewswire.com

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

August 14, 2026 | benzinga.com

Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants

August 12, 2026 | globenewswire.com

OTLK Up More Than 300% in 3 Months: Here's What You Should Know

August 10, 2026 | zacks.com

Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

August 6, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS, OTLK, INDP, and CNTB Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

$6.22 +0.01 (+0.16%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$6.25 +0.03 (+0.48%)

As of 06:40 AM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Connect Biopharma NASDAQ:CNTB

$1.93 -0.83 (-30.07%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$2.06 +0.13 (+6.53%)

As of 08:42 AM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Indaptus Therapeutics NASDAQ:INDP

$1.16 -0.01 (-0.85%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$1.18 +0.02 (+1.64%)

As of 08:30 AM Eastern

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Oncobiologics NASDAQ:OTLK

$0.65 +0.02 (+3.62%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$0.65 +0.00 (+0.15%)

As of 08:42 AM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALGS, OTLK, INDP, and CNTB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALGS, OTLK, INDP, and CNTB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALGS, OTLK, INDP, and CNTB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS, OTLK, INDP, and CNTB Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

Connect Biopharma NASDAQ:CNTB

Indaptus Therapeutics NASDAQ:INDP

Oncobiologics NASDAQ:OTLK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALGS, OTLK, INDP, and CNTB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALGS, OTLK, INDP, and CNTB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALGS, OTLK, INDP, and CNTB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS, OTLK, INDP, and CNTB Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

Connect Biopharma NASDAQ:CNTB

Indaptus Therapeutics NASDAQ:INDP

Oncobiologics NASDAQ:OTLK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools